Clinical Trials
4 trialsNCT02089685 2022-09-13
MK-3475-029
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT00090870 2018-07-12
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00467077 2017-03-17
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
California Cancer Consortium
Phase 2 Terminated
NCT00589550 2015-06-08
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated